Cart
sales@molnova.com
PF-04418948
CAS No. 1078166-57-0
PF-04418948( —— )
Catalog No. M10315 CAS No. 1078166-57-0
PF-04418948 (PF 04418948) is a novel potent and selective prostaglandin EP2 receptor antagonist; inhibits prostaglandin E(2)(PGE(2))-induced increase in cAMP in cells with a functional K(B) value of 1.8 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 65 | In Stock |
|
| 2MG | 38 | In Stock |
|
| 5MG | 60 | In Stock |
|
| 10MG | 86 | In Stock |
|
| 25MG | 186 | In Stock |
|
| 50MG | 315 | In Stock |
|
| 100MG | 348 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePF-04418948
-
NoteResearch use only, not for human use.
-
Brief DescriptionPF-04418948 (PF 04418948) is a novel potent and selective prostaglandin EP2 receptor antagonist; inhibits prostaglandin E(2)(PGE(2))-induced increase in cAMP in cells with a functional K(B) value of 1.8 nM.
-
DescriptionPF-04418948 (PF 04418948) is a novel potent and selective prostaglandin EP2 receptor antagonist; inhibits prostaglandin E(2)(PGE(2))-induced increase in cAMP in cells with a functional K(B) value of 1.8 nM; attenuates the butaprost-induced cutaneous blood flow response in rats; orally active.(In Vitro):PF-04418948 (2 μM; 90 min) inhibits prostaglandin E2 (PGE2)-induced increase in cAMP.(In Vivo):PF-04418948 (oral gavage; 1, 3, and 10 mg/kg; once) attenuats the butaprost-induced cutaneous blood flow response.
-
In VitroPF-04418948 (2 μM; 90 min) inhibits prostaglandin E2 (PGE2)-induced increase in cAMP. Cell Viability Assay Cell Line:CHO cells Concentration:2 μM Incubation Time:90 min Result:Inhibited prostaglandin E2 (PGE2)-induced increase in cAMP in cells expressing EP2 receptors with a functional KB value of 1.8 nM.
-
In VivoPF-04418948 (oral gavage; 1, 3, and 10 mg/kg; once) attenuats the butaprost-induced cutaneous blood flow response. Animal Model:Sprague Dawley rats Dosage:1, 3, and 10 mg/kg Administration:Oral gavage; 1, 3, and 10 mg/kg; once Result:Reduced the peak and AUC butaprost-induced cutaneous blood flow response in a dose-dependent fashion.
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetProstaglandin Receptor
-
RecptorPGE2
-
Research AreaOther Indications
-
IndicationOther Disease
Chemical Information
-
CAS Number1078166-57-0
-
Formula Weight409.407
-
Molecular FormulaC23H20FNO5
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESCOC1=CC2=C(C=C1)C=C(C=C2)OCC3(CN(C3)C(=O)C4=CC=C(C=C4)F)C(=O)O
-
Chemical Name3-Azetidinecarboxylic acid, 1-(4-fluorobenzoyl)-3-[[(6-methoxy-2-naphthalenyl)oxy]methyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. af Forselles KJ, et al. Br J Pharmacol. 2011 Dec;164(7):1847-56.
2. Birrell MA, et al. Br J Pharmacol. 2013 Jan;168(1):129-38.
3. Kach J, et al. J Biol Chem. 2014 Mar 14;289(11):7505-13.
molnova catalog
related products
-
Treprostinil diethan...
Treprostinil diethanolamine (UT-15C) is a potent agonist of EP2, DP1, and IP, with values of 3.6, 4.4, and 32.1 nM for EP2, DP1, and IP, respectively, and 212, 826, 2505, and 4680 nM for EP1, EP4, EP3, and FPKi, respectively.
-
Saikogenin D
Saikogenin D is isolated from?Bupleurum chinense, has anti-inflammatory effects. Saikogenin D activates epoxygenases that converts arachidonic acid to epoxyeicosanoids and dihydroxyeicosatrienoic acids, and the metabolites secondarily inhibit prostaglandin E2 (PGE2) production. Saikogenin D results in an elevation of [Ca2+]i due to Ca2+ release from intracellular stores.
-
CAY10526
CAY10526 is a selective mPGES-1 inhibitor that acts as an inhibitor of the NF-κB signaling pathway.
